Treatment with 31000mg rituximab resulted in significantly greater depletion ( lower B cell and plasmablast numbers between 8 and 28weeks ) paralleled by significantly better EULAR and ACR20 response rates at 40weeks ( p = 0.035 and p = 0.027 , respectively ) and 52weeks ( p = 0.021 and p = 0.043 , respectively ) compared with 21000mg .